Advertisement

Topics

Pfizer Reports Positive Phase 2 Data Of JAK Inhibitors In Alopecia Areata

08:13 EDT 15 Sep 2018 | FinanzNachrichten

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) reported results from its Phase 2a study of PF-06651600, an oral Janus kinase 3 inhibitor, and PF-06700841, a tyrosine kinase 2/JAK1 inhibitor, compared...

Original Article: Pfizer Reports Positive Phase 2 Data Of JAK Inhibitors In Alopecia Areata

NEXT ARTICLE

More From BioPortfolio on "Pfizer Reports Positive Phase 2 Data Of JAK Inhibitors In Alopecia Areata"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...